New Board Members to Drive Strategic Innovation and Growth in Radiopharmaceutical Therapies
ST. LOUIS, Mo., October 15, 2024 – TAG1 Inc., a pioneering company specializing in the supply of medical radioisotopes for Targeted Alpha Therapies (TAT), is pleased to announce the appointment of four distinguished leaders to its Board of Directors. Each of these professionals brings unique expertise and a shared commitment to advancing cancer treatment through innovative radiopharmaceutical solutions.
Carolyn Anderson, Ph.D. – Simon-Ellebracht Professor of Medicinal Chemistry, University of Missouri-Columbia
Dr. Anderson is a renowned researcher in molecular imaging and theranostics. Her work focuses on the development of radiolabeled biomolecules for PET imaging and targeted radiopharmaceutical therapy of cancer. With a passion for training the next generation of scientists, she brings decades of experience in designing novel radiotracers and advancing medical research through interdisciplinary collaboration.
Dimitrios Mantzilas – Chief Technology Officer, Precirix
Mr. Mantzilas is a pioneer in the field of radiopharmaceuticals with deep expertise in nuclear medicine. As a leader in the development and production of radiopharmaceuticals, he has a proven track record of taking innovations from concept to market, contributing to the advancement of personalized medicine. His industry insight and regulatory expertise will be invaluable as TAG1 expands its impact in the radiopharmaceutical space.
Castor Armesto – General Counsel, Earthrise Energy
With over 17 years of legal experience, Mr. Armesto has provided strategic oversight on numerous high-profile corporate transactions, mergers and acquisitions, and regulatory matters. His expertise in corporate governance and building high-performing teams will strengthen TAG1’s operational and legal strategies as the company navigates its growth and partnerships.
Rahul Singhvi, Sc.D., MBA – Co-Founder and CEO, Resilience
Mr. Singhvi is an accomplished executive in the biotechnology and pharmaceutical industry with extensive experience in the development and manufacturing of gene therapies, vaccines, and biological products. His leadership in building and operating successful biotech companies, along with his expertise in business development and finance, will help guide TAG1’s strategic direction and long-term growth.
TAG1’s CEO, Sumit Verma, expressed his enthusiasm for the new Board:
“Each of our new board members brings a unique perspective and invaluable expertise that will be instrumental in guiding TAG1’s vision and expanding our role in revolutionizing cancer treatment through radiopharmaceutical innovation.”
The addition of these respected leaders to TAG1’s Board marks a significant step forward in the company’s mission to provide cutting-edge cancer therapies and broaden the availability of critical isotopes for targeted treatments.
About TAG1 Inc.
TAG1 Inc. is dedicated to revolutionizing cancer treatment by supplying high-purity medical radioisotopes essential for Targeted Alpha Therapies (TAT). Utilizing its proprietary Targeted Alpha Generator 1 (TAG1), the company empowers nuclear radiopharmacies, hospital networks, and research institutions to produce their own supply of Lead-212 isotopes. Through strategic partnerships and innovative technology, TAG1 strives to accelerate the development of personalized and precision medicine, offering new hope and improved outcomes for patients worldwide.
